Physician profile
John Heinzerling
NPI 1306045752
$28,562.98
in general payments reported to CMS, 2019-2025
8 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,371 · 2020: $12K · 2021: $5,694 · 2022: $2,504 · 2023: $451 · 2024: $120 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,280 · Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,280.00 |
| Food and Beverage | $742.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26,517.72 | 2019-2025 | Imfinzi |
| Siemens Medical Solutions USA, INC. | $602.50 | 2022-2025 | Truebeam |
| Visionrt, INC. | $500.00 | 2020 | |
| Elekta, INC. | $343.78 | 2021-2023 | Elekta Medical Linear Accelerator |
| Viewray Technologies INC | $301.26 | 2021 | |
| Varian Medical Systems, INC. | $182.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.63 | 2023 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Heinzerling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.